An Israeli medtech company is using artificial intelligence to help oncologists decide the best and most effective course of treatment for their cancer patients.
OncoHost’s main focus is on treatments for non-small cell lung cancer (NSCLC). According to the World Cancer Research Fund, lung cancer is the second most common cancer (after breast cancer) and responsible for 12.2 percent of new cases of the disease.
In fact, OncoHost CEO Ofer Sharon tells NoCamels, lung cancer “is the number one killer” among patients with this form of the disease.
Comments are closed.